Tim Scannell Joins Longeviti Neuro Solutions as Chair
Longeviti Neuro Solutions, a pioneering company at the forefront of neurotechnology, has made a significant leadership change by appointing Tim Scannell as the Chair of its Board of Directors. This strategic move comes alongside an exciting new partnership that will enhance the company's growth capabilities.
Strategic Partnership for Growth
This announcement is particularly noteworthy because Longeviti has secured a $10 million capital infusion from Soleus Capital. This infusion represents a strategic partnership aimed at accelerating various initiatives, including hiring, product development, and advancing medical education efforts both nationally and internationally.
Tim Scannell’s Impressive Track Record
Scannell's experience in the medical device arena spans more than three decades, primarily with Stryker Corporation, where he held numerous key leadership roles. His journey there entailed transitioning from foundational roles in sales and marketing to significant executive leadership positions, ultimately becoming the President and COO. His comprehensive experience will be invaluable for Longeviti as it seeks to navigate a rapidly evolving sector.
Vision for the Future
Currently, Scannell continues to be an influential figure in MedTech. He serves on multiple boards, providing strategic insight to a range of companies, particularly those intersecting with neurosciences. In his new role at Longeviti, he is expected to offer critical guidance and oversight, contributing directly to the strategic planning processes.
Acknowledging the Value of Innovation
The partnership with Soleus Capital is a testament to the potential observed in Longeviti's innovative technologies aimed at addressing complex brain disorders. The investment will significantly aid Longeviti in pursuing its mission to enhance patient care through state-of-the-art neurotechnology platforms.
“Tim’s leadership brings esteemed perspectives from his decades in the MedTech sector, which is crucial as we refine our strategies and enhance our presence in neurotechnology,” said Jesse Christopher, Co-Founder and CEO of Longeviti Neuro Solutions. This sentiment reflects the confidence and optimism surrounding Scannell's appointment.
Scannell’s Enthusiasm for the Role
In his own words, Scannell expressed, “I easily said ‘yes' to joining the Board of Directors for Longeviti due to the remarkable talent at the company. Longeviti's technology is set to revolutionize patient care in neurosciences, benefiting not only the healthcare industry but also shareholders and employees.”
Soleus Capital’s Commitment
Soleus Capital has recognized the potential within Longeviti and is enthusiastic about supporting its growth trajectory. Following detailed assessments, Ben Lund, a Partner at Soleus Capital, stated, “We were impressed by Longeviti’s dedication to innovation and strong operational outcomes.” This partnership signals substantial future growth as Longeviti aims to expand its outreach to clinicians and patients alike.
About Longeviti Neuro Solutions
Longeviti Neuro Solutions is committed to transforming the lives of those with neurological conditions through advanced solutions. The Baltimore-based company is known for its capacity to manufacture and develop innovative products that are helping thousands of patients. Their current solutions are utilized in over 120 hospitals globally, benefiting thousands of individuals.
Contact Information
For media inquiries, please reach out to Nicole Halsey or Natalie Van Buskirk at Polished Nichols PR & Marketing via email at nicole@polishednichols.com or natalie@polishednichols.com.
Frequently Asked Questions
What is the focus of Longeviti Neuro Solutions?
Longeviti is dedicated to developing innovative neurotechnology solutions aimed at improving the lives of patients with complex brain disorders.
Who has been appointed as Chair of the Board of Longeviti?
Tim Scannell, who previously served as the President and COO of Stryker Corporation, has been appointed Chair.
What is the significance of the partnership with Soleus Capital?
The $10 million partnership aims to accelerate hiring, product development, and educational efforts in the medical field.
How long has Tim Scannell been involved in the MedTech industry?
Tim Scannell has over thirty years of experience in the medical device market, primarily with Stryker Corporation.
In which geographical areas does Longeviti operate?
Longeviti operates in over 120 hospitals globally, with a focus on enhancing patient care throughout various regions.
